LU90829I2 - Tepoxalin-zubrin et ses d-riv-s pharmaceutiquement acceptables - Google Patents

Tepoxalin-zubrin et ses d-riv-s pharmaceutiquement acceptables

Info

Publication number
LU90829I2
LU90829I2 LU90829C LU90829C LU90829I2 LU 90829 I2 LU90829 I2 LU 90829I2 LU 90829 C LU90829 C LU 90829C LU 90829 C LU90829 C LU 90829C LU 90829 I2 LU90829 I2 LU 90829I2
Authority
LU
Luxembourg
Prior art keywords
zubrin
tepoxalin
pharmaceutically acceptable
acceptable derivatives
derivatives
Prior art date
Application number
LU90829C
Other languages
English (en)
Original Assignee
Ortho Pharma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ortho Pharma Corp filed Critical Ortho Pharma Corp
Publication of LU90829I2 publication Critical patent/LU90829I2/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/76—Unsaturated compounds containing keto groups
    • C07C59/84—Unsaturated compounds containing keto groups containing six membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/76—Unsaturated compounds containing keto groups
    • C07C59/88—Unsaturated compounds containing keto groups containing halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
LU90829C 1986-05-29 2001-09-10 Tepoxalin-zubrin et ses d-riv-s pharmaceutiquement acceptables LU90829I2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US86799686A 1986-05-29 1986-05-29
US07/042,661 US4826868A (en) 1986-05-29 1987-04-29 1,5-Diaryl-3-substituted pyrazoles pharmaceutical compositions and use

Publications (1)

Publication Number Publication Date
LU90829I2 true LU90829I2 (fr) 2001-11-12

Family

ID=26719497

Family Applications (1)

Application Number Title Priority Date Filing Date
LU90829C LU90829I2 (fr) 1986-05-29 2001-09-10 Tepoxalin-zubrin et ses d-riv-s pharmaceutiquement acceptables

Country Status (21)

Country Link
US (1) US4826868A (fr)
EP (1) EP0248594B1 (fr)
JP (1) JP2512751B2 (fr)
KR (1) KR960007163B1 (fr)
CN (1) CN1028227C (fr)
AU (1) AU596844B2 (fr)
CA (1) CA1337122C (fr)
DE (2) DE3788244T2 (fr)
DK (1) DK170202B1 (fr)
ES (1) ES2059377T3 (fr)
FI (1) FI94340C (fr)
HK (1) HK14094A (fr)
HU (1) HU221300B1 (fr)
IE (1) IE63856B1 (fr)
IL (1) IL82671A0 (fr)
LU (1) LU90829I2 (fr)
NL (1) NL300057I2 (fr)
NO (2) NO172236C (fr)
NZ (1) NZ220353A (fr)
PH (1) PH25126A (fr)
PT (1) PT84964B (fr)

Families Citing this family (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4898952A (en) * 1987-05-29 1990-02-06 Ortho Pharmaceutical Corporation Regioselective synthesis of a 1,5-disubstituted pyrazole
AU611437B2 (en) * 1987-05-29 1991-06-13 Ortho Pharmaceutical Corporation Pharmacologically active 2- and 3-substituted (1',5'-diaryl-3-pyrazolyl)-n-hydroxypropanamides and method for synthesizing the same
JPS63307841A (ja) * 1987-05-29 1988-12-15 オーソ・フアーマシユーチカル・コーポレーシヨン １，５‐ジ置換ピラゾール類の製造法
CA1334975C (fr) * 1987-11-13 1995-03-28 James H. Holms Composes inhibiteurs de type lipoxygenase contenant des groupes furane et pyrrole
US5096919A (en) * 1989-01-05 1992-03-17 Ciba-Geigy Corporation Pyrrolylphenyl-substituted hydroxamic acid derivatives
US4960787A (en) * 1989-02-06 1990-10-02 Ciba-Geigy Corporation Certain pyrrolyl-substituted hydroxamic acid derivatives
US4994482A (en) * 1989-07-31 1991-02-19 Bristol-Myers Squibb Company Arylpyrazol derivatives as anti-platelet agents, compositions and use
PH27357A (en) * 1989-09-22 1993-06-21 Fujisawa Pharmaceutical Co Pyrazole derivatives and pharmaceutical compositions comprising the same
CA2036192A1 (fr) 1990-02-13 1991-08-14 Nicholas Meanwell Acides carboxyliques heterocycliques et esters
US4956379A (en) * 1990-02-13 1990-09-11 Bristol-Myers Squibb Company Pyrazole carboxylic acids and esters and inhibition of blood platelet aggregation therewith
FR2665898B1 (fr) * 1990-08-20 1994-03-11 Sanofi Derives d'amido-3 pyrazole, procede pour leur preparation et compositions pharmaceutiques les contenant.
CA2052950A1 (fr) * 1990-10-10 1992-04-11 David P. Evitts Microemulsions aqueuses de tepoxalin a usage ophtalmique
US5366987A (en) * 1991-08-22 1994-11-22 Warner-Lambert Company Isoxazolyl-substituted alkyl amide ACAT inhibitors
US5260458A (en) * 1991-09-26 1993-11-09 Ortho Pharmaceutical Corporation 2-oxo tetrahydrofuran compounds
US5117054A (en) * 1991-09-26 1992-05-26 Ortho Pharmaceutical Corporation N-hydroxy, N-methyl propanamides
US5550147A (en) * 1992-02-05 1996-08-27 Fujisawa Pharmaceutical Co., Ltd. Pyrazole derivatives, processes for preparation thereof and pharmaceutical composition comprising the same
IL104311A (en) * 1992-02-05 1997-07-13 Fujisawa Pharmaceutical Co Pyrazole derivatives, processes for the preparation thereof and pharmaceutical compositions containing the same
FR2692575B1 (fr) * 1992-06-23 1995-06-30 Sanofi Elf Nouveaux derives du pyrazole, procede pour leur preparation et compositions pharmaceutiques les contenant.
GB9312853D0 (en) * 1993-06-22 1993-08-04 Euro Celtique Sa Chemical compounds
US5387602A (en) * 1993-08-30 1995-02-07 Ortho Pharmaceutical Corporation 1.5-diphenyl-3-(N-hydroxycarbamoyloxyalkyl)pyrazoles
IL111613A0 (en) * 1993-11-12 1995-01-24 Rhone Poulenc Rorer Ltd Substituted phenyl compounds, their preparation and pharmaceutical compositions containing them
CA2277954A1 (fr) * 1993-11-30 1995-06-08 G.D. Searle & Co. Benzenesulfonamides de pyrazolyle substitues destines au traitement des inflammations
US5591776A (en) * 1994-06-24 1997-01-07 Euro-Celtique, S.A. Pheynl or benzyl-substituted rolipram-based compounds for and method of inhibiting phosphodiesterase IV
US5922751A (en) * 1994-06-24 1999-07-13 Euro-Celtique, S.A. Aryl pyrazole compound for inhibiting phosphodiesterase IV and methods of using same
AU3815495A (en) * 1994-11-08 1996-05-31 Eisai Co. Ltd. Pyrazole derivatives exhibiting anti-inflammatory and analgesic effects
JPH10508032A (ja) * 1994-12-13 1998-08-04 ユーロ−セルティーク，エス．エイ． アリールチオキサンチン類
EP0799040B1 (fr) * 1994-12-13 2003-08-20 Euroceltique S.A. Thioxanthines trisubstituees
US6025361A (en) * 1994-12-13 2000-02-15 Euro-Celtique, S.A. Trisubstituted thioxanthines
CA2223154A1 (fr) * 1995-06-02 1996-12-05 G.D. Searle & Co. Derives heterocyclo-substitues d'acide hydroxamique utilises comme inhibiteurs de la cyclo-oxygenase-2 et de la 5-lipoxygenase
ATE301457T1 (de) * 1995-06-12 2005-08-15 Searle & Co Mittel, enthaltend einen cyclooxygenase-2 inhibitor und einen 5-lipoxygenase inhibitor
US6166041A (en) * 1995-10-11 2000-12-26 Euro-Celtique, S.A. 2-heteroaryl and 2-heterocyclic benzoxazoles as PDE IV inhibitors for the treatment of asthma
US6075016A (en) * 1996-04-10 2000-06-13 Euro-Celtique S.A. 6,5-fused aromatic ring systems having enhanced phosphodiesterase IV inhibitory activity
US5783597A (en) * 1997-03-04 1998-07-21 Ortho Pharmaceutical Corporation 2,5-disubstituted thiophenes: inhibitors of 5-lipoxygenase and inducible cyclooxygenase (COX-2) enzymes, composition and use
IT1300055B1 (it) * 1998-04-17 2000-04-05 Boehringer Ingelheim Italia Eterocicli con anello a 5 termini difenil-sostituiti loro procedimento di preparazione e loro impiego come farmici
US6191147B1 (en) 1998-12-24 2001-02-20 Ppd Discovery, Inc. Pyrazole compounds and uses thereof
IL142341A0 (en) * 1999-08-03 2002-03-10 Ortho Mcneil Pharm Inc Process for preparing 1,5-diaryl-3-substituted pyrazoles
EP2316468A1 (fr) 2002-02-22 2011-05-04 Shire LLC Système de distribution et méthodes de protection et d'administration de dextroamphetamine
UA79804C2 (en) * 2002-07-03 2007-07-25 Janssen Pharmaceutica Nv Cck-1 receptor modulators
WO2004016592A1 (fr) * 2002-08-14 2004-02-26 Ppd Discovery, Inc. Inhibiteurs de prenylation et leurs methodes de synthese et d'utilisation
US6649638B1 (en) * 2002-08-14 2003-11-18 Ppd Discovery, Inc. Prenylation inhibitors and methods of their synthesis and use
WO2004016741A2 (fr) * 2002-08-14 2004-02-26 Ppd Discovery, Inc. Inhibiteurs de la prenylation contenant du dimethylcyclobutane, leurs methodes de synthese et leur utilisation
AU2003275637A1 (en) * 2002-10-24 2004-05-13 Wakamoto Pharmaceutical Co., Ltd. Pyrazole-4-alkanoate derivatives inhibiting cyclooxygenase and 5-lipoxygenase
WO2004050632A1 (fr) * 2002-12-02 2004-06-17 Fujisawa Pharmaceutical Co., Ltd. Derives de pyrazole utiles comme inhibiteurs de cox-i
EP1613614A2 (fr) * 2003-04-03 2006-01-11 Merck & Co., Inc. Modulateurs au pyrazole a substitution diaryle du recepteur-5 de glutamate metabotropique
US20050020565A1 (en) * 2003-07-02 2005-01-27 Jones Todd K. CCK-1 receptor modulators
WO2005005393A2 (fr) * 2003-07-02 2005-01-20 Janssen Pharmaceutica N.V. Modulateurs du recepteur de cck-1
RU2387646C2 (ru) * 2003-08-29 2010-04-27 Рэнбакси Лабораториз Лимитед Ингибиторы фосфодиэстеразы типа-iv
WO2005037271A2 (fr) * 2003-10-17 2005-04-28 Tanabe Seiyaku Co., Ltd. Agent d'ouverture de canaux k actives par le calcium a conductance elevee
US20070259874A1 (en) * 2003-11-26 2007-11-08 Palle Venkata P Phosphodiesterase Inhibitors
US7250434B2 (en) * 2003-12-22 2007-07-31 Janssen Pharmaceutica N.V. CCK-1 receptor modulators
US20060004195A1 (en) * 2004-06-30 2006-01-05 Xiaohu Deng Alpha,beta-unsaturated esters and acids by stereoselective dehydration
WO2007031838A1 (fr) 2005-09-16 2007-03-22 Ranbaxy Laboratories Limited Pyrazolo[3,4-b]pyridines substituees en tant qu'inhibiteurs de la phosphodiesterase
EA200900472A1 (ru) * 2006-09-22 2009-10-30 Ранбакси Лабораторис Лимитед Ингибиторы фосфодиэстеразы iv типа
WO2008035316A2 (fr) * 2006-09-22 2008-03-27 Ranbaxy Laboratories Limited Inhibiteurs de phosphodiestérase
EP1958947A1 (fr) 2007-02-15 2008-08-20 Ranbaxy Laboratories Limited Inhibiteurs de la phosphodiestérase de type 4
SI2124944T1 (sl) * 2007-03-14 2012-05-31 Ranbaxy Lab Ltd Derivati pirazolo b piridina kot inhibitorji fosfodiesteraze
US20110130403A1 (en) * 2007-03-14 2011-06-02 Ranbaxy Laboratories Limited Pyrazolo [3, 4-b] pyridine derivatives as phosphodiesterase inhibitors
US20110009463A1 (en) * 2007-10-17 2011-01-13 Yuri Karl Petersson Geranylgeranyl transferase inhibitors and methods of making and using the same
EP2116539A1 (fr) 2008-04-25 2009-11-11 Laboratorios Del. Dr. Esteve, S.A. 1-aryl-3-aminoalkoxy-pyrazoles en tant que ligands améliorant les effets analgésiques des opioïdes et réduisant leur dépendance
EP2353591A1 (fr) 2010-02-04 2011-08-10 Laboratorios Del. Dr. Esteve, S.A. Ligands sigma pour la potentialisation de l'effet analgésique d'opioïdes et d'opiacés dans la douleur post-opératoire et en atténuant la dépendance
EP2353598A1 (fr) 2010-02-04 2011-08-10 Laboratorios Del. Dr. Esteve, S.A. Ligands sigma pour utilisation dans la prévention et/ou le traitement de la douleur post-opératoire
EP2388005A1 (fr) 2010-05-21 2011-11-23 Laboratorios Del. Dr. Esteve, S.A. Ligands sigma pour la prévention et/ou le traitement du vomissement induit par la chimiothérapie ou la radiothérapie
EP2395003A1 (fr) * 2010-05-27 2011-12-14 Laboratorios Del. Dr. Esteve, S.A. Composés pyrazoliques en tant qu'inhibiteurs du récepteur sigma
WO2011161615A1 (fr) * 2010-06-24 2011-12-29 Ranbaxy Laboratories Limited Inhibiteurs de la 5-lipoxygénase
WO2011161645A1 (fr) * 2010-06-25 2011-12-29 Ranbaxy Laboratories Limited Inhibiteurs de la 5-lipoxygénase
CA2803880C (fr) * 2010-06-28 2018-09-25 President And Fellows Of Harvard College Composes pour inhiber la proliferation cellulaire
US8492424B2 (en) * 2010-07-01 2013-07-23 Allergan, Inc. Compounds act at multiple prostaglandin receptors giving a general anti-inflammatory response
EP2415471A1 (fr) 2010-08-03 2012-02-08 Laboratorios Del. Dr. Esteve, S.A. Utilisation de ligands sigma dans l'hyperalgie induite par opioïdes
EP2524694A1 (fr) 2011-05-19 2012-11-21 Laboratorios Del. Dr. Esteve, S.A. Utilisation de ligands sigma dans la douleur liée au diabète de type 2
EP2861562B1 (fr) * 2012-06-14 2018-05-09 Mayo Foundation For Medical Education And Research Dérivés de pyrazole en tant qu'inhibiteurs de stat3
SG11201604480PA (en) 2013-12-17 2016-07-28 Esteve Labor Dr SEROTONIN-NOREPINEPHRINE REUPTAKE INHIBITORS (SNRIs) AND SIGMA RECEPTOR LIGANDS COMBINATIONS

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE755924A (fr) * 1969-09-12 1971-02-15 Byk Gulden Lomberg Chem Fab Derives d'acide pyrazole-4-acetique, leur procede de preparation et medicaments en contenant
GB1373212A (en) * 1970-12-07 1974-11-06 Wyeth John & Brother Ltd Pyrazole compounds
US3974176A (en) * 1973-08-16 1976-08-10 Byk-Gulden Lomberg Chemische Fabrik Gmbh Halogen pyrazoles derivatives, a method for producing these halogen pyrazole derivatives and medicaments containing them
DE2633992A1 (de) * 1975-08-08 1978-02-09 Schering Ag Neue pyrazol-derivate, ihre herstellung und verwendung
DE2906252A1 (de) * 1979-02-19 1980-08-28 Merck Patent Gmbh Pyrazolderivate, diese enthaltende pharmazeutische zubereitungen und verfahren zu ihrer herstellung
DE3205187A1 (de) * 1982-02-13 1983-08-25 Hoechst Ag, 6230 Frankfurt Substituierte phenylpyrazolderivate, verfahren zu ihrer herstellung, arzneimittel auf basis dieser verbindungen, sowie deren verwendung

Also Published As

Publication number Publication date
DK273587D0 (da) 1987-05-27
NO872228L (no) 1987-11-30
NO172236C (no) 1993-06-23
KR960007163B1 (ko) 1996-05-29
DE3788244D1 (de) 1994-01-05
FI94340C (fi) 1995-08-25
CN87103953A (zh) 1987-12-09
PH25126A (en) 1991-02-19
EP0248594A3 (en) 1988-11-17
HU221300B1 (en) 2002-09-28
CA1337122C (fr) 1995-09-26
PT84964A (en) 1987-06-01
NL300057I2 (nl) 2002-01-02
HUT68247A (en) 1995-06-28
FI872379A0 (fi) 1987-05-28
FI872379A7 (fi) 1987-11-30
HK14094A (en) 1994-03-04
NO172236B (no) 1993-03-15
DE10199049I2 (de) 2003-01-09
EP0248594A2 (fr) 1987-12-09
DE3788244T2 (de) 1994-04-14
DK170202B1 (da) 1995-06-12
NZ220353A (en) 1989-05-29
CN1028227C (zh) 1995-04-19
US4826868A (en) 1989-05-02
AU7360887A (en) 1987-12-10
DE10199049I1 (de) 2002-01-10
IL82671A0 (en) 1987-11-30
JP2512751B2 (ja) 1996-07-03
JPS6322080A (ja) 1988-01-29
FI94340B (fi) 1995-05-15
EP0248594B1 (fr) 1993-11-24
AU596844B2 (en) 1990-05-17
IE63856B1 (en) 1995-06-14
NO2001016I1 (no) 2001-10-01
KR870011100A (ko) 1987-12-21
DK273587A (da) 1987-11-30
PT84964B (pt) 1990-02-08
ES2059377T3 (es) 1994-11-16
IE871403L (en) 1987-11-29
NO872228D0 (no) 1987-05-27
NL300057I1 (nl) 2001-12-01

Similar Documents

Publication Publication Date Title
LU91039I2 (fr) Proteq flu et ses dérivés pharmaceutiquement acceptables
LU90736I2 (fr) Agenerase-amprenavir et ses d-riv-s pharmaceutiquement acceptables
LU90769I2 (fr) Capecitabine et ses d-riv-es pharmaceutiquement acceptables (xeloda)
LU90219I2 (fr) Tolcapone et ses dérivés pharmaceutiquement acceptables (TASMAR)
LU91205I2 (fr) Ciclesonide et ses dérivés pharmaceutiquement acceptables (alvesco)
LU90484I2 (fr) Novorapid - insuline asparte et ses sels et derives pharmaceutiquement acceptables
LU88736I2 (fr) Cefquinome et ses dérivés pharmaceutiquement acceptables (COBACTAN)
LU88750I2 (fr) VENLAFAXINE et ses dérivés pharmaceutiquement acceptables
LU90069I2 (fr) Lercanidipine et ses sels et dérivés pharmaceutiquement acceptables (Zanidip)
FR2631232B1 (fr) Adsorbats medicamenteux
DK255587D0 (da) Tetrahydronaphthalen- og indanderivater
LU91072I2 (fr) Eplerenone et ses sels pharmaceutiquement acceptables - INSPRA
DK366787A (da) Tetrahydronaphthalen- og indanderivater
KR910700249A (ko) 신규 치료학적 활성 화합물 및 그의 제조 방법
LU90844I2 (fr) es Riamet et ses d-riv-s pharmaceutiquement acceptabl
DK40788A (da) Phenylsubstituerede purinonderivater
FI884019A0 (fi) Korrigering av foerstaerkning och fas i en tvaovaegsmottagare.
LU88790I2 (fr) Moxidectin et ses dérivés pharmaceutiquement acceptables
KR900006397U (ko) 드로우어웨이식 보울 엔드밀
TR24895A (tr) PIRIMIDIN TüREVLERI,BUNLARIN ISTIHSAL EDILMESI VE KULLANILMASI
DK254488D0 (da) Azaindol- og indolizinderivater
LU88843I2 (fr) Ropivacaine et ses dérivés pharmaceutiquement acceptables (Naropine R)
DE68927610D1 (de) Antikörper-Arzneimittel Konjugale
DK641587A (da) Benzofuran- og benzopyranderivater
DK555489A (da) Tetralinderivater